☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Innate Pharma
The US FDA Lifts its Clinical Hold on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sézary Syndrome
January 4, 2024
Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome
November 3, 2023
Innate Pharma Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Lacutamab
October 5, 2023
Innate Pharma Entered into an Exclusive License Agreement with Takeda to Develop Antibody Drug Conjugates for Celiac Disease
April 3, 2023
Innate Pharma Presents Preliminary P-II (TELLOMAK) Trial Results of Lacutamab for the Treatment of Advanced Mycosis Fungoides
September 26, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.